Biodexa Pharmaceuticals reported total assets of $16.86M and total liabilities of $4.12M for the quarter ended Jun 2026, down 4.5% year over year. This balance sheet covers 24 quarters of results from Dec 2013 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance SheetBalance Sheet | Dec2013 | Dec2014 | Dec2015 | Jun2016 | Dec2016 | Jun2017 | Dec2017 | Jun2018 | Dec2018 | Jun2019 | Dec2019 | Jun2020 | Dec2020 | Jun2021 | Dec2021 | Jun2022 | Dec2022 | Jun2023 | Dec2023 | Jun2024 | Dec2024 | Jun2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||||||
| Current Assets | ||||||||||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 21.64M | 8.05M | 17.75M | 5.38M | 2.97M | 11.38M | 14.33M | 5.33M | 10.29M | 13.58M | 7.79M | 3.42M | 6.59M | 7.60M | 6.39M | 2.09M | 5.54M | 11.49M | 4.28M | |||||
| Cash & Current Investments | 21.64M | 8.05M | 17.75M | 5.38M | 2.97M | 11.38M | 14.33M | 5.33M | 10.29M | 13.58M | 7.79M | 3.42M | 6.59M | 7.60M | 6.39M | 2.09M | 5.54M | 11.49M | 4.28M | |||||
| Receivables - NetNet Receivables | 3.00M | 3.36M | 4.36M | 0.94M | 1.68M | 3.25M | 1.30M | 4.52M | 0.78M | 1.94M | 1.40M | 1.21M | 1.14M | 0.81M | 2.43M | 8.24M | 6.17M | 5.10M | 3.89M | |||||
| Receivables - OtherOther Receivables | 1.07M | 1.14M | 1.99M | 0.58M | 4.52M | 0.30M | 0.53M | 0.36M | 0.36M | 0.16M | 0.09M | |||||||||||||
| Receivables | 4.07M | 3.36M | 5.50M | 0.94M | 3.66M | 3.83M | 5.82M | 4.52M | 1.08M | 1.94M | 1.93M | 1.58M | 1.14M | 1.17M | 2.43M | 8.41M | 6.17M | 5.18M | 3.89M | |||||
| Finished Goods | 1.00M | 1.26M | ||||||||||||||||||||||
| Inventory | 1.00M | 1.19M | 1.26M | 1.30M | 0.80M | |||||||||||||||||||
| Prepaid Assets | 0.18M | 0.45M | 0.35M | 0.82M | 0.45M | |||||||||||||||||||
| Current Assets | 27.41M | 15.23M | 24.98M | 26.79M | 7.13M | 18.16M | 18.01M | 12.64M | 12.64M | 9.73M | 15.88M | 5.65M | 9.16M | 8.95M | 9.51M | 11.06M | 12.34M | 16.76M | 8.87M | |||||
| Non-Current Assets | ||||||||||||||||||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 3.40M | 3.55M | 3.40M | 3.30M | 2.52M | 2.22M | 2.82M | 1.17M | 0.74M | 1.73M | 1.56M | 1.00M | 0.87M | 0.73M | 0.55M | 0.41M | 0.26M | 0.12M | 0.03M | |||||
| Long-Term Investments | ||||||||||||||||||||||||
| Goodwill | 18.01M | 8.75M | 2.92M | 3.02M | 1.20M | |||||||||||||||||||
| Intangibles | 20.49M | 13.58M | 12.82M | 13.24M | 19.02M | 3.74M | 27.55M | 7.08M | 7.60M | 7.97M | ||||||||||||||
| Goodwill & Intangibles | 33.97M | 39.54M | 37.16M | 16.19M | 15.71M | 15.69M | 16.23M | 0.96M | 21.36M | 21.15M | 1.20M | 0.01M | 0.01M | 3.75M | 7.60M | 7.09M | 7.74M | 7.60M | 7.97M | |||||
| Long-Term Deferred Tax | 9.95M | 12.77M | 2.16M | 2.10M | 2.18M | 22.81M | 21.58M | 24.07M | 24.97M | 27.61M | ||||||||||||||
| Other Non-Current Assets | 17.70M | 11.87M | ||||||||||||||||||||||
| Non-Current Assets | 42.25M | 43.69M | 41.18M | 20.09M | 18.82M | 18.01M | 22.50M | 2.13M | 0.74M | 1.73M | 1.56M | 1.01M | 0.88M | 4.47M | 8.15M | 7.49M | 8.00M | 7.72M | 7.99M | |||||
| Assets | 69.66M | 58.91M | 66.16M | 46.88M | 25.95M | 36.18M | 40.51M | 14.77M | 13.38M | 11.45M | 17.43M | 6.66M | 10.04M | 13.42M | 17.66M | 18.55M | 20.34M | 24.48M | 16.86M | |||||
| Liabilities | ||||||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||||||
| Accounts Payables | 10.33M | 8.65M | 10.76M | 4.50M | 2.67M | 3.20M | 5.89M | 3.43M | 1.68M | 2.82M | 1.47M | 1.74M | 2.21M | 1.58M | 2.14M | 4.40M | 1.94M | 3.49M | 2.17M | |||||
| Notes Payables | 0.72M | 0.69M | 0.90M | 4.19M | 0.18M | 0.20M | 0.19M | 0.21M | 0.22M | 0.69M | ||||||||||||||
| Payables | 10.33M | 9.37M | 10.76M | 5.19M | 2.67M | 4.10M | 5.89M | 7.62M | 1.68M | 3.00M | 1.47M | 0.20M | 1.94M | 2.42M | 1.58M | 2.36M | 4.40M | 2.63M | 3.49M | 2.17M | ||||
| Other Accumulated Expenses | 0.58M | 0.68M | 0.72M | 0.76M | 0.81M | |||||||||||||||||||
| Short term Debt | 0.66M | 0.49M | 0.47M | 0.54M | 0.27M | 0.20M | 0.19M | 0.22M | 0.76M | 0.08M | ||||||||||||||
| Current Deferred Revenue | ||||||||||||||||||||||||
| Curent Deferred Tax LiabilityCurent Deferred Tax | 0.58M | 0.68M | 0.72M | 0.76M | 0.81M | |||||||||||||||||||
| Total Current Liabilities | 11.48M | 9.43M | 11.24M | 8.26M | 3.14M | 0.21M | 7.43M | 9.04M | 4.07M | 0.07M | 2.49M | 2.29M | 2.88M | 7.09M | 4.40M | 6.32M | 3.40M | 8.25M | 3.68M | |||||
| Non-Current Liabilities | ||||||||||||||||||||||||
| Non-Current Debt | 1.99M | 1.59M | 8.31M | 8.05M | 1.12M | 0.49M | 7.44M | 0.13M | 0.08M | 0.94M | 0.84M | 0.56M | 0.48M | 0.38M | 0.26M | 0.15M | ||||||||
| Liabilities from Discontinued OperationsLiabilities from Discont. Ops | 3.08M | |||||||||||||||||||||||
| Non-Current Deferred Tax LiabilityNon-Current Deferred Tax | ||||||||||||||||||||||||
| Other Non-Current Liabilities | -0.60M | -0.10M | 0.87M | 1.42M | 2.13M | 2.25M | 0.75M | 0.19M | 0.10M | 0.46M | 5.30M | 1.96M | 1.64M | 1.25M | 0.87M | 0.44M | ||||||||
| Total Non-Current Liabilities | 1.99M | 1.59M | 8.31M | 8.05M | 1.33M | 0.49M | 7.44M | 0.13M | 0.15M | 0.94M | 0.84M | 0.56M | 0.48M | 0.38M | 2.23M | 1.79M | 1.25M | 0.87M | 0.44M | |||||
| Total Liabilities | 13.47M | 11.02M | 19.55M | 16.32M | 4.47M | 4.80M | 14.87M | 9.17M | 4.22M | 6.26M | 3.32M | 2.85M | 3.36M | 7.47M | 6.63M | 8.10M | 4.65M | 9.12M | 4.12M | |||||
| Shareholder's Equity | ||||||||||||||||||||||||
| Total Debt | 2.65M | 2.31M | 8.80M | 8.74M | 1.59M | 1.39M | 7.98M | 4.32M | 0.35M | 1.12M | 1.03M | 0.20M | 0.75M | 0.69M | 0.59M | 0.48M | 0.91M | 0.69M | 0.08M | |||||
| Common Equity | 56.19M | 47.90M | 46.61M | 30.56M | 21.48M | 31.38M | 25.65M | 5.60M | 9.16M | 14.11M | 9.09M | 3.81M | 6.68M | 5.96M | 11.04M | 10.44M | 15.69M | 15.36M | 12.74M | |||||
| Liabilities and Shareholders Equity | 69.66M | 58.91M | 66.16M | 46.88M | 25.95M | 36.18M | 40.51M | 14.77M | 13.38M | 11.45M | 17.43M | 6.66M | 10.04M | 13.42M | 17.66M | 18.55M | 20.34M | 24.48M | 16.86M | |||||
| Retained Earnings | -72.63M | -88.31M | -100.34M | -112.66M | -113.89M | -119.31M | -130.92M | -144.93M | -166.88M | -173.79M | -172.51M | -163.17M | -175.31M | -184.35M | -187.01M | -188.77M | -211.47M | -209.83M | -208.88M | |||||
| Preferred Shares |
Pull Biodexa Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=BDRX&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "BDRX", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=BDRX&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();